Notable mutations included CTNNB and TTN in ACC (Fig. 4a), MET and RERE in KIRP (Fig. 4c), TP53, RB1, FGFR3, FAT3, and AHNAK in BLCA (Fig. 4d), TP53, FAT4, and CUBN in PRAD (Fig. 4e), TP53, CSMD3, RB1, CNGA3 and RTPRB in LIHC (Fig. 4f), showing significant variation between high- and low-expression ALYREF groups. This evidence concerns the gene CUBN and bladder transitional cell carcinoma.